Logo Thing main logo
Logo Thing main logo

Profile

Dr. Smita Shrikant Kulkarni
Name : Dr. Smita Shrikant Kulkarni
Designation : Scientist G
Division : Virology
DOB : 20-05-1969
Email ID : skulkarni@nariindia.org, skulkani.nari@gov.in
Area Of Interest : 1. HIV Virology and Molecular Virology • HIV and viral co-infecting pathogens • HIV characterization • HIV neutralizing antibodies • In vitro testing of indigenously developed anti-HIV drug and microbicide candidates • HIV Clinical Trials • Validation of newer assays and quality control in molecular diagnostic laboratories 2. Rickettsiology • Isolation and characterization of rikettsial pathogens • In vitro drug sensitivity analysis of isolated rickettsial spp
Awards and Honours
  1. Outstanding Researcher for 2017, Antiviral Research Society, India.
  2. Letter of Appreciation from Union of Iranian Students Islamic Association (UISA) & Iranian Embassy, November 2017
  3. Research Scholar, Duke University Medical Centre, Durham, USA, 2006.
  4. Fogarty AITRP Fellowship in HIV Immunology/Virology, Johns Hopkins University, Baltimore, MD; National Institutes of Health, Bethesda, MD; New York University Medical Centre, NY, USA, 2000.
  5. Colombo Plan Health General Fellowship in HIV Plus Microbiology Screening (AIDS/Blood Screening Technology), Regional Blood Transfusion Centre, New Castle Upon Tyne; Edinburgh University, Edinburgh and Dundee University, Dundee, 1992.
Work Experience

Work Experience

Post Held

Employer

Duration

Scientist G

National AIDS Research Institute, Pune

 

01-09-2019 - To date

Scientist F

2014 - 2019

Scientist E

2009 - 2014

Scientist D

2005 - 2009

Senior Research Officer

2000 - 2005

Technical Officer

1992 - 2000

Technical Officer

National Institute of Virology, Pune

 

1990 - 1992

Research Assistant

1987 - 1990

Research Assistant

1981 - 1987

 

List of Grant Recieved

List of grants received

Sr.No.

Title of Project

Duration

Funding Agency

Role

1.

Development of diagnostic kit for rapid and early detection of Orientia tsutsugamushi based on isothermal recombinase polymerase amplification and lateral flow analysis in collaboration with ICMR-RMRC, Gorakhpur, UP.

2019-2021

ICMR

Co-Investigator

2

 

Development of indigenous handheld SERS platform for rapid detection of Human Immunodeficiency Virus-1 in collaboration with IIT-D, Delhi.

2018-2020

Dept of Health Research

 

Co-Investigator

3

Isolation, Characterization and in vitro drug sensitivity testing of rickettsial spp from AES cases reported from various parts of India.

2017-2019

 

ICMR

Principle Investigator

4

Estimating HIV-1 RNA levels in DBS specimens using Abbott HIV-1 viral load kit (Phase II).

2018

NACO

Principle Investigator

5

Validation of the GenXpert HIV-1 Quant Assay for HIV-1 RNA estimation.

2015

WHO

Co-Investigator

6

Identification of Potential Anti-HIV Natural Product Analogs Using Molecular Docking and Medicinal Chemistry Approaches, in collaboration with NIPER, Mohali, India.

2013-2017

DBT & ICMR

Co-Principle Investigator

7

Identification of anti-HIV leads from plant sources and determination of mechanism of action in collaboration with NCL, Pune, India.

2013-2016

DBT & ICMR

Principle Investigator

8

Anti-HIV testing of newly developed glycosides in collaboration with Mysore University.

2010-  2013

 

Co-Investigator

9

Evaluation of efficacy of a microbicide in humanized polyherbal (Basant) anti HIV vaginal mouse model and its mode of action in collaboration with OSU, USA.

2009-2012

NIH & ICMR,

Principle Investigator

(NARI)

10

Design, synthesis and biological evaluation of HIV-1 RT-inhibitors 4-Thioazolidinone compounds. Funded by ICMR in Oct 2009 in collaboration with CDRI, India.

2009-2012

ICMR

Principle Investigator

(NARI)

11

In vitro testing of indigenously developed active principles for identification and characterization of candidate anti-retroviral microbicides in collaboration with NCL, Pune; NIRRH, Mumbai and CU Shah College of Pharmacy, Mumbai, India.

2006-2011

DBT & ICMR

Principle Investigator

 

12

Design and Development of anti-viral compounds as inhibitors of HIV replication in collaboration with Univ. of Allahabad, Allahabad, India.

2006-2010

DBT & ICMR,

 

Co-Investigator

13

Design and synthesis of novel non-nucleoside reverse transcriptase inhibitors for treatment of AIDS and opportunistic infections associated AIDS including tuberculosis in collaboration with Birla Institute of Technology and Science, Pilani.

2006-2008

ICMR

 

Co-Investigator

14

Development of facility for In-vitro anti- HIV screening and immuno-modulatory testing.

2006-2010

Dept of Ayush, Govt of India.

Co-Investigator

15

In vitro anti-HIV testing of candidate Microbicide agents, in collaboration with Programme for Appropriate Technology in Health (PATH) USA.

2005

PATH

Principle Investigator

 

16

Prolyl Nucleic Acids: a novel class of polychiral antigene/antisense therapeutic agents and their applications in molecular biotechnology for Anti HIV activity.

1999- 2001

DBT

Co-Investigator

17

Testing of traditional medicines for toxicity, anti-HIV and immunopotentiating activity.

1997- 2002

ICMR

Co-Investigator

 

Conference/Training/Workshop Attended

Conferences/Trainings/Workshops Attended

Conferences attended:

  1. Chief Guest and key note speaker for the Quality Improvement Programme on “Prospective Approach on Advanced Biotechnology, Cell Culture and Bioinformatics in Modern Research”, JSS Academy of Higher Education, Ooty, TN, (1st March 2019).
  2. International AIDS Conference, Durban, South Africa, 18-22 July 2016. (Recepient of International scholarship).
  3. 3rd Antiviral Congress Amsterdam, The Netherlands, 12-14 October 2014. (Travel grant, DST & ICMR).
  4. Modern Methods in Detection, Identification and Quantification of Microorganims”, Bharati Vidyapith University, Pune and Association of Microbiologists of India, Pune, India. 28th February 2014. (Invited speaker and Chief Guest).
  5. Asia-Pacific Virology conference (Virocon-2013), Amity University, Noida, India 17-20th December 2013 (Organized HIV/AIDS session & Chaired two sessions).
  6. 3rd Biennial International Conference on “New Developments in Drug Discovery from Natural Products and Traditional Medicines (DDNPTM), NIPER, Mohali, India. 23-25 November 2012. (Invited speaker).
  7. International conference on “Anti-virals” organized by the International Consortium for Anti-Virals (ICAV), New Delhi, India. 7-10 February 2012.
  8. Preparatory symposium on “Translational research in Infectious Diseases”, ICMR, New Delhi under the ICMR-HGF (Germany) MoU. 28-29 November 2011. (Invited speaker).
  9. International Microbicides Conference (M2010), Pittsburgh, USA, (Recepient of International scholarship).
  10. 2nd Indo-Japanese International Joint Symposium on “Overcoming Intractable Infectious Diseases Prevalent in Asian Countries” Tokyo, Japan, 23-24 December 2008. (Invited speaker).
  11. 2008 International AIDS Vaccine Conference, Cape Town, South Africa, 13-16 October 2008. (Recepient of International scholarship).
  12. International Conference on “Fundamental and Translational Research on HIV/AIDS: Global Perspectives”, National Institute for Research on Reproductive Health, Mumbai, 5-8 October 08. (Invited speaker).
  13. International Microbicide 2008 Conference, New Delhi, India. 24-27 February 2008.
  14. Symposium on “Present advances in Industrial Pharmaceutical Biotechnology”, Alard College of Pharmacy, Hinjewadi, Pune, 16th February 2008. (Invited speaker).
  15. 34th Annual Conference of Indian Immunology Society, National AIDS Research Institute, Pune, India. 16-18 December 07.
  16. International Conference on “Contemporary issues and future challenges in drug development”, Mumbai, India. 9th October 2007.
  17. Symposium on HIV/AIDS: Biology, Immunology and Vaccinology, New Delhi. 13th-14th March 2007.
  18. International Conference on “Molecular & Cellular Biology & Therapeutics of HIV and associated diseases”, Hyderabad, India. 12th-14th January 2007. (Invited speaker).
  19. 2nd World Ayurveda Congress & Arogya, Pune, India. 10th-12th November 2006. (Invited speaker).
  20. 2005 International AIDS Vaccine Conference, Montreal, Canada. Abstract No: A229. 6-9 September 2005. (Recepient of International scholarship).
  21. Symposium: Phytopharma 2005: The emerging field of Biotechnology. Aurangabad, India. 4-6th February 2005. (Invited speaker).
  22. 92nd Indian Science Congress, Ahmedabad, India. 3-7 January 2005.
  23. Symposium on “Microbicides in development and their potential for prevention of STIs and pregnancy”. NIRRH, Mumbai, 21-22 June 2004.
  24. 3rd Annual Conference of the Indian Society of Hospital Waste Management, Armed Forces Medical College, Pune, India, 17-18 May 2003.
  25. 10th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, 10-14th February 2003. (Recipient of International scholarship).
  26. International meeting of the Institute of Human Virology, 10-15 September 2000, Baltimore, USA.
  27. 27th Annual Conference of the Indian Immunology Society, Agra, India. December 10-13, 2000.
  28. 5th International Conference on Emerging Infections in the Pacific Rim, Chennai, India, 7-9 January 2000.
  29. Asia-Pacific HIV/AIDS conference, Chiang Mai, Thailand. 1996.
  30. HIV/AIDS conference, NARI, Pune, 1995.
  31. International AIDS conference, Mumbai, India. 1990. (Invited speaker)
  32. Annual Conference of Association of Microbiologists of India, Nagpur, 1986.
  33. Annual Conference of Association of Microbiologists of India, Pantanagar, 1984.

Attended by students, staff and collborators

  1. International Conference (Combat HIV 19) on “Biology and Therapeutics of HIV & Associated Infection”, University of Hyderabad, Hyderabad, 19-21 January 2019.
  2. 22nd International AIDS Conference, Amsterdam, Netherlands, 23-27 July 2018.
  3. The Frontiers of Retrovirology Conference, Erlangen, Germany, 12-16 September 2016.
  4. 18th International Union against Sexually Transmitted Infections (IUSTI) Asia Pacific Conference, Bangkok Thailand, 11-14 November 2014.
  5. 4th Biennial International Conference on New Developments in Drug Discovery from Natural products and Traditional Medicines (DDNPTM)”, NIPER, Mohali, India, 20– 22 November 2014
  6. 11th International Symposium on Advances in Technology and Business potential of New Drug Delivery Systems Controlled Release Society - Indian Chapter, Mumbai, India. 16-17th Feb 2011.
  7. 4th International Conference on, “Innovations in Translating Technologies through Clinical Pharmacology”, South Asian Chapter of American College of Clinical Pharmacology, Mumbai, India, 10-12th December 2010.
  8. International Microbicides Conference (M2010), Pittsburgh, USA, Abstract: 142. 22-25 May 2010.

 Trainings acquired:

  1. Training on CDC Dried Tube Specimens (DTS) for HIV-1 viral load proficiency testing (PT) Programme Technology Transfer, HIV laboratory, Centre for Disease Control & Prevention, Atlanta, USA from 23-27 October 2017.
  2. Training on “Cultivation of Orentia tsutsugamushi” at the Rickettsial Zoonosis branch, Centre for Disease Control & Prevention, Atlanta, USA from 30th October to 3rd November 2017.
  3. Good Clinical Practices (GCP) training conducted by Collaborative Institutional Training Initiative, HPTN.
  4. Human Research, Human Subjects Protection (HSP) conducted by Collaborative Institutional Training Initiative, HPTN.
  5. Good Clinical and Laboratory Practices (GCLP) training conducted by Pharmaceutical Product Development, USA.
  6. Training for the transportation of Dangerous Goods conducted by Saf-T-Pak Inc, AB, USA.
  7. Human Subjects Research Education. Sept 2003, conducted by Johns Hopkins School of Hygiene and Public Health, JHU, USA.
  8. Clinical vaccine trials and Good Clinical Practice. Eight weeks Web based distance education course in Aug-Sep 2003 conducted by Johns Hopkins Bloomberg School of Public Health, JHU, MD, USA.
  9. Training in Flow Cytometry (CD4/CD8 estimation), Becton Dickinson, San Hose, CA, USA, 1991.

Workshops attended:

  1. Attended a workshop on “Current Regulatory Requirements for Members of Institutional Ethics Committees” National Centre for Cell Science (NCCS), University of Pune, Pune, India. 11 - 12 February 2015.
  2. Formulation Development for Multiple Prevention Technologies, ICMR Headquarter, New Delhi, India. 7th May 2013.
  3. Grantsmanship and Peer Review, ICMR, New Delhi, India. 28-29 October 2010.
  4. BSL3 training/workshop at NIV, Pune, 1st December 2008. 
  5. Laboratory Biosecurity and Biosafety, NIV, Pune, India. 2-4 May 2006.
  6. Good Clinical Laboratory Practices (GCLP), Johannesburg, South Africa, 6-8 February 2006.
  7. NIH Grant application process: Grantsmanship workshop. 13-14th September 2004.
  8. Reproductive Health Research Mehthodology. NIRRH, Mumbai, 21-22 June 2004. 
  9. Competence building for writing up proposals and seeking grants from national and international agencies for scientists and medical colleges, NIRRH, Mumbai, 11-13 September 2002.
  10. Indo-French workshop on Genetic and Virological Aspects of HIV infection, NARI, Pune, India. November 23-24, 1998.
Number of Publications : 83
List of Publications

List of Publications

Patents: 2

  1. Triaminotriazine Picolinonitrile derivatives as potent Reverse Transcriptase inhibitor of HIV-1. (Publication No. WO 2016059647 A2) filed in India and Patent Cooperation Treaty (PCT/IN2015/000386) in collaboration with Shri Chhatrapti Shivaji College, Dr. Babasaheb Ambedkar Marathwada University, Auranagabad.
  2. Microbiocides from plant extracts for protection against HSV-2 infection. (Publication No WO2013164858A1) filed in India and Patent Cooperation Treaty (PCT/IN2013 /000293) in collaboration with NCL, Pune.

 

Publications in scientific journals: 77

  1. Sacks J, Fong Y, Gonzalez M, Andreotti M, Baliga S, Garrett N, Jordan J, Karitah E, Kulkarni S, Mor O, Mosha F, Ndlovu Z, Plantier J, Saravanan S, Scott L, Peter T, Doherty M and Vojnov L. 2019. Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure. AIDS 2019, 33:1881–1889. doi: 10.1097/QAD.0000000000002303.

 

  1. Kurmi M, Sahu A, Singh I.P, Kulkarni S and Singh S. 2019. Stability behaviour of antiretroviral drugs and their combinations. 9: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their activity and toxicity. Journal of Pharmaceutical and Biomedical Analysis. doi:10.1016/j.jpba.2019.112911.
  2. Chitre T, Patil S, Sujalegaonkar A, Asgaonkar K, Khedkar V, Garud D, Jha P, Gaikwad S, Kulkarni S, Choudhari A, Sarkar 2019. Non Nucleoside Reverse Transcriptase Inhibitors, Molecular Docking Studies and Antitubercular Activity of Thiazolidin-4-one Derivatives, Current Computer-Aided Drug Design, doi: 10.2174/1573409915666181221102903.
  3. Kumar S, Gupta S, Abadi L, Gaikwad S, Desai D, Bhutani K, Kulkarni S*, Singh IP.* 2019. Synthesis and In–vitro Anti–HIV–1 Evaluation of Novel Pyrazolo [4,3–c]pyridin–4–one Derivatives. European Journal of Medicinal Chemistry,183: 111714 *: Equal contribution. org/10.1016/j.ejmech.2019.111714.
  4. Yadav P, Souvik Sur S, Desai D, Kulkarni S, Sharma V and Tandon V*. 2019. Interaction of HIV-1 integrase with polypyrimidine tract binding protein and associated splicing factor (PSF) and its impact on HIV-1 replication. Retrovirology, 16:1-18. org/10.1186/s12977-019-0474-1.

 

6.      Dhande J, Angadi M, Murugavel K, Poongulali S, Nandagopal P, Vignesh R, Ghate M, Kulkarni S, Thakar M. 2018. Brief Report: The Anti-HIV-1 ADCC-Mediating Antibodies From Cervicovaginal Secretions of HIV-Infected Women Have an Ability to Mediate Lysing of Autologous CD4+ HIV-Infected Cells. JAIDS, 79: 277-282. doi: 10.1097/QAI.0000000000001788.

7.      Kumar, S.; Gupta, S.; Gaikwad, S.; Abadi, L.; Bhutani, K. K.; Kulkarni, S.*; Singh, I. P.* Design, synthesis and in vitro evaluation of novel anti-HIV 3-pyrazol-3-yl-pyridin-2-one analogs, Medicinal Chemistry. *: Equal contribution. doi: 10.2174/1573406414666181106125539.

8.      Shah, P.; Abadi, L. F.; Gaikwad, S.; Chaudhari, D.; Kushwah, V.; Jain, S.; Bhutani, K. K.; Kulkarni, S.*; Singh, I. P.* 2018. Synthesis and Biological Evaluation of 8 Hydroxyquinoline hydrazones for Anti-HIV1 and Anticancer Potential, Chemistry Select, 3, 10727-10731. *: Equal contribution. doi.org/10.1002/slct.201802283.

9.      Desai D, Bhutkar M, Kulkarni S. 2018. Infectivity and Growth Kinetics of Herpes Simplex Virus type-2 in MOLT4 CCR5+ and CEM CCR5+ T cell lines. Microb Pathog. 2018;123: 82-88. doi: 10.1016/j.micpath.2018.06.035.

10.   Shah P, Naik D, Jariwala N, Bhadane D, Kumar S, Kulkarni S*, Bhutani K, Singh IP*. 2018. Synthesis of C-2 and C-3 substituted quinolines and their evaluation as anti-HIV-1 agents. Bioorg. Chem. 80:591-601. *: Equal contribution. doi: 10.1016/j.bioorg.2018.07.016

11.   Saxena V; Ghate M; Bichare S; Khan I; Majumdar R; Angadi M; Kulkarni S; Paranjape R; Thakar M. 2018. Increased degranulation of immune cells is associated with higher cervical viral load in HIV infected women. AIDS,  2:1939-1949. doi: 10.1097/QAD.0000000000001925.

  1. Singh D, Ghate M, Godbole S, Kulkarni S, Thakar M. 2018. Functional invariant Natural Killer T cells secreting cytokines are associated with non-progressive HIV-1 infection but not with suppressive ART. Front Immunol. 24;9:1152. org/10.3389/fimmu.2018.01152.
  2. Mahajan S., Gupta S., Jariwala N., Bhadane D., Bhutani K., Kulkarni S.* and Singh I. 2018. Design, synthesis and anti-HIV-1 activity of modified styrylquinolines. Letters in Drug Design & Discovery. *: Equal contribution. doi: 10.2174/1570180815666171212143339.
  3. Karade S., Chaturbhuj D., Sen S., Joshi R., Kulkarni S., Subramanian S. and Gangakhedkar R. HIV drug resistance following a decade of free antiretroviral therapy program in India: A review. Int. J. Infect. Dis.; 66:33-41. doi: 10.1016/j.ijid.
  4. Kulkarni S., Jadhav S., Khopkar P., Sane S., Londhe R., Chimanpure V., Dhilpe V., Ghate M., Yelagate R., Panchal N., Rahane G., Kadam D., Gaikwad N., Rewari B. and Gangakhedkar R. 2017. GeneXpert HIV-1 Quant Assay, a new tool for scale up of viral load monitoring in the success of ART programme in India. BMC Infect Dis. 17: 506. doi:  10.1186/s12879-017-2604-5. PMCID: PMC5521114.
  5. Karade , Kulkarni S., Patil A., Londhe R., Salve S., Ghate M., Kadam D., Joshi R., Rewari B. and Gangakhedkar R. 2017. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study. PLoS ONE 12(8). doi.org/10.1371/journal.pone.0181889.
  6. Khopkar P, Rohamare M, Kulkarni S. Indirect Immunofluorescence assay for HIV-1 and HIV-2 confirmation in dual infection. Current Research HIV/AIDS, CRHA-114, Image Article, Open access journal. doi: 10.29011/2575-7105. 100014.
  7. Gupta S., Kumar S., Jariwala N., Bhadane D., Bhutani K., Kulkarni S.*, Singh I. Tembamide and its analogs as anti-HIV-1 agents: Need for evaluation against different HIV-1 strains before anti-HIV-1 lead. Letters in Drug Design & Discovery. *.Equal contribution. doi: 10.2174/1570180814666170419115526.
  8. Suryawanshi , Jadhav S., Makwana N., Desai D., Chaturbhuj D., Sonawani A., Thomas S., Murugesan V., Katti S., Tripathy S., Paranjape R. and Kulkarni S. 2017. Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains. Bioorg Chem. doi: 10.1016/j.bioorg.2017.02.007.
  9. Kulkarni S., Kale S., Ghodke U., Risbud A. and Kulkarni S. 2017. Evaluation of the quality indicators in laboratories at National AIDS Research Institute Pune, India, National Journal of Community Medicine. 8(2): 47-51.
  10. Singh D., Ghate M., Godbole S., Kulkarni S., and Thakar M. 2017. CD1d restricted Natural killer T cells are preserved in Indian long term non progressors (LTNPs). J AIDS. doi: 10.1097/QAI.0000000000001322.
  11. Saxena V., Bichare S., Singh D., Ghate M., Godbole S., Kulkarni S., Gangakhedkar R., Paranjape R. and Thakar M. 2017. Low immune activation is associated with higher frequencies of central memory T cell subset in a cohort of Indian long term non-progressors,AIDS Research Human Retroviruses, 33:121-125. doi:10.1089/aid.2016.0210.
  12. Jadaun P., Khopkar P. and Kulkarni, S., 2016. Repurposing Phytochemicals as Anti-HIV Agents. Journal of Antivirals & Antiretrovirals, 8:139-141. doi: 10.4172/jaa.1000150.
  13. Durge A., Jadaun P., Wadhwani A., Chinchansure A., Said M., Thulasiram H., Joshi S. and Kulkarni S. Acetone and methanol fruit extracts of Terminalia paniculata inhibit HIV-1 infection in vitro. Nat. Prod. Res. doi.org/10.1080/14786419.2016.1258561.
  14. Karade S., Ghate M., Chaturbhuj D., Kadam D., Shankar S., Gaikwad N., Gurav S., Joshi R., Kulkarni S., Kurle S., Paranjape R., Rewari B., Gangakhedkar R. 2016. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India. Medicine, 95:e4886. doi: 10.1097/MD.0000000000004886.
  15. Hajare R., Kulkarni S., Thakar M. and Paranjape R. 2016. Technology development and design of novel 1, 3, 5-tri substituted-1h-indole-2, 3-dione hiv-1 inhibitors with displays strategic nanomolar cytotoxicity. World J. Pharm. & Pharm. Sci. 5 (6): 391-397.
  16. Cohen M., Chen Y., McCauley M., Gamble T., Hosseinipour M., Kumarasamy N., Hakim J., Kumwenda J., Grinsztejn B., Pilotto J., Godbole S., Chariyalertsak S., Santos B., Mayer K., Hoffman I., Eshleman S., Piwowar Manning E., Cottle L., Zhang X., Makhema J., Mills L., Panchia R., Faesen S., Eron J., Gallant J., Havlir D., Swindells S., Elharrar V., Burns D., Taha T., Nielsen Saines K., Celentano D., Essex M., Hudelson S., Redd A., and Fleming T., for the HPTN 052 Study Team. 2016. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. Engl. J. Med. 375:830-9. doi: 10.1056/NEJMoa1600693.
  17. Jadaun P., Kulkarni S., Yadav D., Khopkar P., Bisen P. 2016. The Emerging Link between HIV Therapy and Diabetes. Bone Marrow Res. 4 (2):1000168. doi:10.4172/2329-8820.1000168.
  18. Karade S., Patil A., Ghate M., Kulkarni S., Kurle S., Risbud A., Rewari B., Gangakhedkar R. 2016. Limited HIV Pretreatment Drug Resistance Among Adults Attending Free Antiretroviral Therapy Clinic of Pune, India. AIDS Research & Human Retroviruses, 32 (4):377-80. doi: 10.1089/AID.2015.0277.
  19. Hajare R, Kulkarni S, Paranjape R. Design Space Filling Model, Synthesis and Evaluation of Novel 2-Indolinone HIV-1 Inhibitors. Int. J. Adv. Res. 3 (12):1332-1335.
  20. Desai D. and Kulkarni S. The Herpes Simplex Virus: Interplay between HSV, host and HIV. Viral Immunology, 28 (10):546-555. doi: 10.1089/vim.2015.0012.
  21. Thio C., Smeaton L., Hollabaugh K., Saulynas M., Hwang H., Saravanan S., Kulkarni S., Hakim J., Nyirenda M., Iqbal H., Lalloo U., Campbell T., Lockman S., Currier J. 2015. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS, 29 (10):1173-82. doi: 10.1097/QAD.0000000000000686.
  22. Ghate M., Mehendale S., Meyer R., Umlauf A., Deutsch R., Kamat R., Thakar M., Risbud A., Kulkarni S., et al. 2015. The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India. Neurovirol., 21 (4):391-8. doi: 10.1007/s13365-015-0329-z.
  23. Said M., Chinchansure A., Nawale L., Durge A., Wadhwani A., Kulkarni S., Sarkar D. and Joshi S. 2014. A new butenolide cinnamate and other biological active chemical constituents from Polygonum glabrum. Prod. Res., 29 (22):2080-6. doi: 10.1080/14786419.2015.1004674.
  24. Maselko M., Joshi R., Prescotta M., Talwar G., Kulkarni S. and Pastey M. 2014. Basant, a polyherbal topical microbicide candidate inhibits different clades of both CCR5 and CXCR4 tropic, lab-adapted and primary isolates of HIV Virus-1 infection in vitro. Virol. Antivir. Res. 3:4. doi:10.4172/2324-8955.1000131.
  25. Jadhav N., Kulkarni S., Mane A., Kulkarni R., Palshetker A., Singh K., Joshi S., Risbud A., Kulkarni S. 2014. Antimicrobial Activity of Plant Extracts against Sexually Transmitted Pathogens. Prod. Res., 29 (16):1562-6. doi: 10.1080/14786419.2014.983919.
  26. Praveena P., Godse A., Pawar M., Kulkarni S. and Sudarsanam D. 2014. In vitro anti-HIV activity studies on Enicostema littorale (Lam) Raynal whole plants. World J. Pharm. Res., 3 (6): 1343-1352.
  27. Singh A., Yadav D., Yadav M., Dhamanage A., Kulkarni S.$ and Singh R.K.$,*. 2014. Molecular Modeling, Synthesis and Biological Evaluation of N-Heteroaryl Compounds as Reverse Transcriptase Inhibitors against HIV-1. Biol. & Drug Des., 85 (3):336-47. $-Equal contribution. doi: 10.1111/cbdd.12397.
  28. Vanangamudi M., Makwana N., Suryawanshi R., Saxena R., Tripathi R., Paranjape R., Kulkarni $, Katti S.$,*. 2014. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. & Medicinal Chem., 22 (12): 3159-3170. $- Equal contribution. doi: 10.1016/j.bmc.2014.04.018.
  29. Khopkar P., Sane S, Bichare S., Verma A., Kulkarni S. 2013. Association of plasma viremia with HIV-1 RNA levels in cervicovaginal lavage secretions in HIV-1 seropositive ART naïve women from Pune, India. Clin. Virol., 58 (4):730-2. doi: 10.1016/j.jcv.2013.10.018.
  30. Khopkar P., Mallav V., Chidrawar S., Kulkarni S. Comparative evaluation of the Abbott HIV-1 RealTime™ assay with the Standard Roche COBAS®Amplicor™ HIV-1 Monitor® Test, v1.5 for determining HIV-1 RNA levels in plasma specimens from Pune, India. J. Virol. Methods, 191 (1):82-87. doi: 10.1016/j.jviromet.
  31. Jennings C., Harty B., Granger S., Wager C., Crump J.A., Fiscus S.A., Bremer J.W. 2012. Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation. Clin. Microbiol., 50 (8):2737-47. (NARI HIV-1 RNA Quality assurance data used for cross-platform analysis, institute acknowledged). doi: 10.1128/JCM.00578-12.
  32. Mane A., Kulkarni S., Ghate M., Risbud A., Thakar M. 2012. HIV-1 RNA shedding in the female genital tract is associated with reduced quantity of Lactobacilli in clinically asymptomatic HIV-positive women. Microbiol. & Infect. Dis., 75 (1): 112–114. doi: 10.1016/j.diagmicrobio.2012.09.009.
  33. Thio C., Smeaton L., Saulynas M., Hwang H., Saravan S., Kulkarni S., Hakim J., Nyirenda M., Iqbal H., Lalloo U., Mehta A., Hollabaugh K., Campbell T., Lockman S., Currier J. 2012. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS, 27 (2):191-201. doi: 1097/QAD.0b013e32835a9984.
  34. Hingankar N., Thorat S., Deshpande A., Rajasekaran S., Chandrasekar C., Kumar S., Srikantiah P., Chaturbhuj D., Datkar S., Deshmukh P., Kulkarni S., Sane S., Reddy D., Garg R., Jordan M., Kabra S., Tripathy S., Paranjape R. 2012. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. Infect. Dis., 54 Suppl 4:S348-54. doi: 10.1093/cid/cis005.
  35. Murugesan V., Tiwari V., Saxena R., Tripathi R., Paranjape R., Kulkarni S., Makwana N., Suryawanshi R., Katti SB. 2011. Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. & Medicinal Chem., 19 (22): 6919–6926. doi: 10.1016/j.bmc.2011.09.018.
  36. Jadhav S., Tripathy S., Kulkarni S., Chaturbhuj D., Ghare R., Bhattacharya J., Paranjape R. 2011. Genetic Conservation in gp36 Transmembrane Sequences of Indian HIV Type 2 Isolates. AIDS Research & Human Retroviruses, 27 (12): 1337-1343. doi: 10.1089/aid.2011.0063.
  37. Gupta A., Bhosale R., Kinikar A., Gupte N., Bharadwaj R., Kagal A., Joshi S., Khandekar M., Karmarkar A., Kulkarni V., Sastry J., Mawe V., Suryawanshi N., Thakar M., Kulkarni S., Tripathy S., Sambarey P., Patil S., Paranjape R., Bollinger R., Jamkar A., Six week extended dose Nevirapine (SWEN) India study Team. 2011. Maternal tuberculosis: A risk factor for mother to child transmission of human immunodeficiency virus. Infect. Dis., 203 (3):358-363. doi.org/10.1093/jinfdis/jiq064.
  38. Cohen M S., Chen YQ., McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, Hakim J., Kumwenda J, Grinsztejn B, Pilotto J., Godbole S, Mehendale S, Chariyalertsak S, Santos B., Mayer K, Hoffman I, Eshleman S, Piwowar-Manning E, Wang L, Makhema J, Mills L., Bruyn Guy de, Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns David, Taha Taha E., Nielsen-Saines K., Celentano D., Essex M. and Fleming T., for the HPTN 052 Study Team. 2011. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. Engl. J. Med., 365 (6):493-505. doi: 10.1056/NEJMoa1105243.
  39. Kulkarni S., Lapedes A., Tang,H.Gnanakaran S., Daniels M., Zhang M., Bhattacharya T., Li M., Polonis V., McCutchan F., Morris L., Ellenberger D., Butera S., Bollinger R., Korber B., Paranjape R. and Montefiori D. 2009. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology, 385 (2):505-20. doi: 10.1016/j.virol.2008.
  40. Rodriguez M., Ding M.’ Ratner D.’ Chen Y.’ Tripathy S.’ Kulkarni S., Chatterjee R., Tarwater P., Gupta P. 2009. High Replication Fitness and Transmission Efficiency of HIV-1 Subtype C from India: Implications for Subtype C Predominance. Virology, 385 (2):416-424. doi: 10.1016/j.virol.2008.
  41. Jadhav S., Tripathy S., Kulkarni S., Agnihotri K., Risbud A. and Paranjape R. 2009. Molecular Phylogenetics of Nearly Full-Length HIV Type 2 envelope Gene Sequences from West India. AIDS Research & Human Retroviruses, 25 (1):115-121. doi: 10.1089/aid.2008.0142.
  42. Moorthy A., Gupta A., Bhosale R., Tripathy S., Sastry J., Kulkarni S., Thakar M., Bharadwaj R., Kagal A., Bhore A., Patil S,, Kulkarni V., Venkataramani V., Balasubramaniam U., Suryavanshi N., Ziemniak C., Gupte N., Bollinger R., Persaud D. for the India SWEN Clinical Trials Team. 2009. Nevirapine resistance and breast milk HIV transmission: Effects of single and extended dose prophylaxis in subtype C HIV infected infants. Plos One, 4 (1): e4096. doi: 10.1371/journal.pone.0004096.
  43. Kulkarni S., Tripathy S., Gangakhedkar R., Jadhav S., Agnihotri K., Sane S., Bollinger R. and Paranjape R. 2008. Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India. AIDS Research & Human Retroviruses, 24 (9):1159-1166. doi: 10.1089/aid.2007.0296.
  44. Rawal R., Tripathi R., Kulkarni S, Paranjape R., Katti S., Pannecouque C. and De Clercq E. 2008. 2-(2,6-Dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1, 3-thiazolidin-4-ones: Anti-HIV agents. Biol. Drug. Des., 72 (2):147–154. doi: 10.1111/j.1747-0285.2008.00683.x.
  45. Zore G B., Winston U., Surwase B., Meshram N., Sangle V., Kulkarni S., Karuppayil S. 2008. Chemoprofile and bioactivities of Taverniera cuneifolia (Roth) Arn: A wild relative and possible substitute of Glycyrrhiza glabra L. Phytomedicine, 15 (4):292-300. doi: 10.1016/j.phymed.2007.01.006.
  46. Rodriguez M., Chengli S., Ratner D., Paranjape R., Kulkarni S., Chatterjee R., Gupta P. 2007. Genetic and Functional Characterization of the LTR of HIV-1 Subtypes A and C Circulating in India. AIDS Research & Human Retroviruses, 23 (11): 1428-33. doi: 10.1089/aid.2007.0152.
  47. Lakhashe S., Kulkarni S., Thakar M., Ghate M. and Paranjape R. 2007. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1. Virology, 359 (2):295-301. doi: 10.1016/j.virol.2006.09.019.
  48. Mehendale S., Ghate M., Kishor K., Sahay S., Gamble T., Godbole S., Thakar M., Kulkarni S., Gupta A., Gangakhedkar R., Divekar A., Risbud A., Paranjape R. and Bollinger R. 2006. Low HIV-1 incidence among married serodiscordant couples in Pune, India. J Acquir. Immune. Syndr, 41 (3):371-373. doi:10.1097/01.qai.0000209905.35620.48.
  49. Kulkarni S., Tripathy S., Agnihotri K., Jatkar N., Jadhav S., Umakanth W., Dhande K., Tondare , Gangakhedkar R. and Paranjape R. 2005. Indian primary HIV-2 isolates and relationship between V3 genotype, biological phenotype and coreceptor usage. Virology, 337 (1):68-75. doi:10.1016/j.virol.2005.04.008.
  50. Manocha M., Pal P., Chitralekha K., Thomas B., Tripathi V., Gupta S., Paranjape R., Kulkarni S., Rao D. 2005. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine, 23 (48-49): 5599-17. doi: 1016/j.vaccine.2005.06.031.
  51. Thakar M., Bhonge L., Lakhashe S., Kumar U. Sane S., Kulkarni S., Mahajan B. and Paranjape Ramesh. 2005. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. Infect. Dis., 192 (5):749-59. doi:10.1086/432547.
  52. Tripathy S., Kulkarni S., Jadhav S., Agnihotri K., Jere A., Kurle S., Bhattacharya S., Singh K., Tripathy S. and Paranjape R. 2005. Subtype B and subtype C HIV type 1 recombinants in the northeastern state of Manipur, India. AIDS Research & Human Retroviruses, 21 (2):152-7. org/10.1089/aid.2005.21.152.
  53. Eshleman S., Hudelson S., Gupta A., Bollinger R., Divekar A., Gangakhedkar R., Kulkarni S., Thakar M., Paranjape R. and Tripathy S. 2005. Limited evolution in the HIV-1 pol region among acute seroconverters in Pune, India. AIDS Research & Human Retroviruses, 21 (1):93-97. doi: 10.1089/aid.2005.21.93.
  54. Mehendale S., Bollinger R., Kulkarni S., Stallings R., Brookmeyer R., Kulkarni S., Divekar A., Gangakhedkar R., Joshi S., Risbud A., Thakar M., Mahajan B., Kale V., Ghate M., Gadkari D., Quinn T., Paranjape R. 2002. Rapid progression in Human Immunodeficiency Virus Type 1 infected seroconverters in India. AIDS Research & Human Retroviruses, 18 (6): 1175-79. doi: 10.1089/08892220260387913.
  55. Cecillia D., Kulkarni S., Tripathy S., Gangakhedkar R., Paranjape R., Gadkari D. 2000. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology, 271 (2):253-258. doi: 1006/viro.2000.0297.
  56. Kulkarni S., Tripathy S., Paranjape R., Mani N., Joshi D., Patil U. and Gadkari D. 1999. Isolation and preliminary characterization of two HIV-2 strains from Pune, India. Ind J Med Res, 109:123-130. PMID:10402758.
  57. Lole K., Bollinger R., Paranjape R., Gadkari D., Kulkarni S., Novak N., Ingersoll R., Sheppard H. and Ray S. 1999. Full-length Human Immunodeficiency Virus Type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. Virol, 73 (1):152-160. PMCID: PMC103818.
  58. Gadkari D., Moore D., Shepard H., Kulkarni S., Mehendale S. and Bollinger R. Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J.Med.Res, 107:1-9. PMID:9529774.
  59. Paranjape R., Kulkarni S., Chanda S., Mehendale S., Jawadekar S., Pratinidhi A. and Rodrigues J. 1997. Evaluation of algorithms of anti-HIV antibody tests (without western blot) on sera from long distance truck drivers. Indian J. Commun. Med, 22 (2):54-57.
  60. Kulkarni S., Bhonde R., Padbidri V. 1995. Comparative studies on the susceptibility of certain primary cultures to Coxiella burnetii. Indian J. Medical Micribiol., 13 (3): 145-149.
  61. Kulkarni S., Thakar M., Rodrigues J. and Banerjee K. 1992. HIV-2 antibodies in serum samples from Maharashtra State. J. Med. Res, [A] 95:213-215. PMID: 1478722.
  62. Thakar M., Rodrigues J., Randive S., Kulkarni S. and Banerjee K. 1991. Circulating Immune complexes in healthy, HIV-antibody positive subjects. J. Med. Res, [A] 93:57-61. PMID:1906833.
  63. Randive S., Thakar M., Kulkarni S., Sukumaran K., Gokhale N., Rodrigues J. and Banerjee K. Prevalence of HIV-1 antibodies in patients attending Tuberculosis clinics in Pune. J. Assoc. Phy. Ind, 39 (5):427. PMID:1960173.
  64. Banerjee K., Rodrigues J., Israel Z., Kulkarni S. and Thakar M. 1989. Outbreak of HIV seropositivity among commercial plasma donors in Pune, India. Lancet, II; 8655:166. PMID:1960173.
  65. Padbidri V., Divekar A., Kulkarni S. and Rodrigues J. 1986. A sporadic case of epidemic (louse born) typhus. Assoc. Phy. Ind., 34 (3):213-214. PMID: 3090015.
  66. Kulkarni S., Bhonde R, Padbidri V. and Wagh U. 1985. Multiplication of Coxiella burnetii in vitro in chick foetal membranes. J. Parasitol, 9:235-237.

Proceedings: 2

  1. Padbidri V., Pant U., Kulkarni S. and Dhanda V. 1984. Multiplication of Coxiella burnetii in Culex bitaeniorhynchus cell line. III Intern. Symposium on “Rickettsiae and Rickettsial diseases” held at Smolenice, Czechoslovakia, 10-14 Sept. pp 235-240.
  2. Khopkar P., Rohamare M., Kulkarni S. 2016. Co-receptor tropism in HIV-1, HIV-2 monotypic and dual infections. The Frontiers of Retrovirology Conference, Erlangen, Germany, 12-16        September 2016. Proceedings of the conference published in Retrovirology (Abstract P4, 2016, 13 (Suppl 1):          68, pg no 13).

 

Book Chapters: 2

  1. Kulkarni S. and Paranjape R. 2005. Role of Non-human primates in HIV/AIDS research. Review article in Book entitled “National Center for Primate Breeding and Research: Vision, Challenges and Opportunities” Edited by Dr. Chander P. Puri and Dr Nirmal K. Ganguly released on 9th Jan 2005, on the occasion of Foundation Stone laying ceremony of the Primate Centre, NIRRH, Mumbai. pg no: 435-454.
  2. Paranjape R., Tripathy S. and Kulkarni S. 2000. Direct evidence of HIV infection. HIV Testing Manual: Laboratory diagnosis, Biosafety and quality control. Publ. National AIDS Control Organization, Ministry of Health and Family Welfare, Govt of India: 75-80.